A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability and Activity of Oral SRT2104 Capsules Administered for 28 days to Subjects with Type 2 Diabetes Mellitus.

Registry ID

EUCTR2009-016537-98

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Sirtris Pharmaceuticals Inc.

Start date

2010-02-17

Completion date

2010-12-22

Last update

2026-08-16

Conditions

• Type II Diabetes Mellitus

Summary

1. To study the effects of SRT2104 vs. placebo on insulin sensitivity including hepatic and muscular insulin sensitivity. 2. To determine the safety and tolerability of 28 days of dosing with 2.0 g SRT2104 in subjects with type 2 diabetes mellitus in a fed state.

Locations

• , , Germany

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
• cfMSC Therapy for Diabetes
• Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
• Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
• Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

View on source registry